RecruitingNCT05516667

Cohort of Patients with Alzheimer's Disease and Their Families.

Pilot Phase of a Prospective Cohort of Patients with Alzheimer's Disease and Their Families


Sponsor

University Hospital, Toulouse

Enrollment

1,000 participants

Start Date

Apr 6, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This is the pilot phase of a longitudinal observational cohort study. The study includes family clusters comprised of a patient with Alzheimer's disease, an informal caregiver and at least one first-degree relative of the patient. The family clusters will be followed-up in expert memory centers and online in order to study risk and prognostic factors (including blood-based biomarkers) in the first-degree relatives and patients, respectively, as well as caregiver health, difficulties and needs. This pilot study is performed to assess the feasibility of conducting a larger-scale study.


Eligibility

Min Age: 18 Years

Inclusion Criteria24

  • AD patients:
  • Probable Alzheimer's disease (clinical and biological NINCDS-ADRDA 2011 criteria)
  • Mild-moderate AD (MMSE ≥15)
  • Sufficiently fluent in French in order to answer study questionnaires
  • Agrees to undergo medical examinations at baseline, 12 and 24 months, as outlined in the protocol
  • Affiliated to French social security
  • Written informed consent
  • Caregivers:
  • Caregiver (defined as assisting the patient in activities of daily living for at least 6 hours per week during the last 6 months) to an AD patient having agreed to participate in the study
  • Age ≥18 years.
  • Sufficiently fluent in French in order to answer study questionnaires
  • Agrees to answer regular questionnaires about their own or the AD patient's health (during visits at study centres or via a secure internet website/postal questionnaires)
  • Affiliated to French social security
  • Written informed consent
  • First-degree relatives:
  • First degree relative of an AD patient having agreed to participate in the study
  • Age ≥18 years.
  • Sufficiently fluent in French in order to answer study questionnaires
  • Agrees to undergo medical examinations at baseline, 12 and 24 months, as outlined in the protocol
  • Agrees to answer regular questionnaires about their own health (via a secure internet website or via postal questionnaires)
  • Affiliated to French social security
  • Written informed consent
  • In order to be included in the study, a familial cluster must be comprised of 2 to 5 people, as follows:
  • Familial cluster of 3 to 5 people: 1 AD patient, 1 caregiver (does not need to be a relative of the patient), 1 to 3 first-degree relatives of the patient

Exclusion Criteria14

  • AD patients:
  • Other brain disorders
  • Autosomal dominant form of AD
  • Under legal protection measure (guardianship, curators, safeguard of justice…)
  • Institutionalized
  • Life expectancy \<2 years
  • Caregivers:
  • Under legal protection measure (guardianship, curators, safeguard of justice…)
  • Diagnosed with a major neurocognitive disorder
  • First-degree relatives:
  • Related to a patient with an autosomal dominant form of dementia
  • Carrier of an autosomal dominant dementia mutation
  • Under legal protection measure (guardianship, curators, safeguard of justice…)
  • Diagnosed with a major neurocognitive disorder

Locations(4)

Hôpitaux Universitaires de Marseille Timone

France, Marseille, France

CMRR Centre de Montpellier

Montpellier, France

CMRR Centre de Rouen

Rouen, France

CMRR - CRC Centre de Toulouse

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05516667


Related Trials